Contributions and limitations of FISH analysis for the diagnosis of central nervous system tumors according to the 2021 WHO classification: Feedback from Sainte-Anne Hospital's Department of Neuropathology

被引：0

作者：

Tauziede-Espariat, Arnault ^{[1
]}

Tartar, Amelie ^{[1
]}

Mehdia, Leila ^{[1
]}

Pucelle, Noemie ^{[1
]}

Lacombea, Joelle ^{[1
]}

Berthaud, Charlotte ^{[1
]}

Brigot, Enola ^{[1
]}

Masse, Joelle ^{[1
]}

Metais, Alice ^{[1
]}

Benzakoun, Joseph ^{[2
]}

Hasty, Lauren ^{[1
]}

Chretien, Fabrice ^{[1
]}

Varleta, Pascale ^{[1
]}

机构：

[1] Ctr Hosp St Anne, GHU Paris Psychiat & Neurosci, Serv Neuropathol, 1 Rue Cabanis, F-75014 Paris, France

[2] Ctr Hosp St Anne, GHU Paris Psychiat & Neurosci, Serv Neuroradiol, F-75014 Paris, France

来源：

ANNALES DE PATHOLOGIE | 2023年 / 43卷 / 06期

关键词：

FISH; Tumors; Central nervous system; BIOPSY;

D O I：

10.1016/j.annpat.2023.06.014

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

The fifth edition of the World Health Organization (WHO) Classification of Tumors of the Central Nervous System has identified many new tumor types and has established, for the first time, essential and desirable diagnostic criteria for each of them. Among these, genetic alterations play an important role associated with morphology. For the first time, epigenetic data can also constitute essential and/or desirable criteria. These genetic abnormalities can be fusions, deletions or gains/amplifications and can thus be detected by fluorescence in situ hybridization techniques. The purpose of this article is to present the advantages and limitations of this technique in reference to its specific use within neuro-oncopathology in light of the 2021 WHO classification.(c) 2023 Elsevier Masson SAS. All rights reserved.

引用

页码：443 / 451

页数：9